Method: Embase, MEDLINE, PubMed, Cochrane and PROS-PERO databases were searched using terms including doctor, education, examination and performance. Inclusion criteria included years 2001-2016, doctors, summative oral examination results, any performance-affecting factor, and the countries Australia, Canada, Ireland, New Zealand, the United Kingdom (UK) and the United States of America. Results were grouped into similar factors and a narrative synthesis was undertaken within each of these groupings.
ANTIBODIES TO SURFACE DOPAMINE-2 RECEPTOR AND N-METHYL-D-ASPARTATE RECEPTOR IN THE FIRST EPISODE OF ACUTE PSYCHOSIS IN CHILDREN
The dopamine and glutamate hypotheses explain the pathophysiology of psychosis in terms of defects in neurotransmission. The recent demonstration of autoantibodies against neurotransmitter receptors expressed on the surface of neuronal cells suggests that immune-mediated mechanisms may define a biological subgroup within psychosis. This study examined, for the first time, a cohort of children presenting with a first episode of psychosis (FEP) for the presence of antibodies to dopamine-2 receptor (D2R) and the NR1 subunit of the N-methyl-D-aspartate receptor (NMDAR). We hypothesised that a subgroup of children from this cohort would have antibodies against these receptors, and that these antibodies would not be present in paediatric controls.
Method: Serum taken during the acute presentation of 43 children with FEP and serum from 43 paediatric control subjects was assessed for the presence of IgG, IgM and IgA antibodies to human D2R and NR1 using a flow cytometry live cell-based assay and immunolabelling of murine primary neurons.
Immunoaffinity purification and immunoabsorption were used to assess the specificity of antibody binding.
Results: Positive immunoglobulin binding to D2R was found in 3 of 43 psychosis patients (3 IgG, 1 IgM, 0 IgA) and to NMDAR in 6 of 43 patients (5 IgG, 1 IgM, 1 IgA). Positive binding was not detected to either receptor in any control patients, as compared with 8 of 43 FEP patients (P < 0.0001). Specificity of binding was confirmed.
Conclusions: For the first time, antibodies to surface D2R and NR1 were detected in paediatric patients with isolated psychosis, suggesting the existence of a subgroup of patients with an immune-mediated mechanism of psychotic disease. This result builds on studies in adults that have shown antibodies against NMDAR in schizophrenia, and represents a novel extension of paediatric studies that demonstrated antibodies to D2R and NMDAR in neuropsychiatric conditions. Objectives: This study aims to determine the effects of feeding interventions (infant and cot positioning, pump vs. gravity feeds) on the frequency of respiratory events in preterm infants, born less than 32 weeks gestation, managed in a tertiary neonatal unit. Primary outcomes were number of events (apnoea, bradycardia and/or desaturation) and percentage of time with SaO 2 oximetry above 88% in a 24-h period. Secondary outcome was percentage of time with oximetry histograms less than 80%.
FEEDING INTERVENTIONS BECAUSE OF RESPIRATORY EVENTS IN PRETERM INFANTS
Methods: FIBRE employs a randomised triple crossover design with conditions of: (i) control (supine/flat position with nasogastric gravity bolus feeds); (ii) positional intervention (propped/prone position with nasogastric gravity bolus feeds) and (iii) feed rate intervention (supine/flat position with continuous pump feeds over 45 min). Each infant experiences each of the three 24-h test conditions over a 3-day period, in a sequence which is randomised. A brief audit was undertaken in order to undertake power calculations and define study parameters.
Design: Clinical research/randomised triple crossover trial. Status: ethics approved, site-specific approved, PHA.
Implementation: FIBRE has received ethical approval by the Gold Coast Hospital and Health Service Human Research Ethics Committee (HERC) (EC00160) and site-specific approval by the Queensland Health District Research Governance Committee at Gold Coast University Hospital in February 2016. FIBRE commenced formally on 01/07/2016 following a series of
